Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BFRG |
---|---|---|
09:32 ET | 535 | 2.9 |
09:38 ET | 471 | 2.96 |
09:41 ET | 175 | 2.885 |
09:45 ET | 149 | 2.905 |
09:48 ET | 600 | 2.9 |
10:03 ET | 7196 | 2.81 |
10:06 ET | 1097 | 2.814 |
10:08 ET | 100 | 2.93 |
10:26 ET | 1891 | 2.902 |
10:33 ET | 841 | 2.925 |
10:35 ET | 1900 | 2.92 |
11:11 ET | 785 | 2.87 |
11:26 ET | 500 | 2.9135 |
11:36 ET | 1064 | 2.9399 |
11:47 ET | 100 | 2.92 |
12:02 ET | 100 | 2.92 |
12:12 ET | 1820 | 2.84 |
12:57 ET | 100 | 2.89 |
01:12 ET | 1000 | 2.8201 |
01:28 ET | 200 | 2.8578 |
01:33 ET | 100 | 2.87 |
01:39 ET | 399 | 2.8757 |
01:44 ET | 100 | 2.9021 |
02:09 ET | 100 | 2.89 |
02:26 ET | 100 | 2.88 |
02:44 ET | 1309 | 2.874 |
03:03 ET | 100 | 2.8999 |
03:27 ET | 250 | 2.9004 |
03:38 ET | 100 | 2.92 |
03:54 ET | 200 | 2.8601 |
03:56 ET | 1000 | 2.9 |
03:57 ET | 371 | 2.87 |
03:59 ET | 349 | 2.91 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Bullfrog AI Holdings, Inc. | 22.5M | -3.2x | --- |
Eom Pharmaceutical Holdings Inc | 22.4M | -4.6x | --- |
Lisata Therapeutics Inc | 22.1M | -1.0x | --- |
Context Therapeutics Inc | 22.0M | -0.9x | --- |
Neurosense Therapeutics Ltd | 21.8M | -1.6x | --- |
Serina Therapeutics Inc | 23.0M | -0.7x | --- |
Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence / machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma (HCC), obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $22.5M |
---|---|
Revenue (TTM) | $65.0K |
Shares Outstanding | 7.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.90 |
Book Value | $0.43 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 345.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8,257.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.